Your Shopping Cart is empty.
Delphi Genetics will be present at BIO 2015 international convention in Philadelphia
Delphi Genetics will be part of the Belgian delegation to BIO 2015 interna
Delphi Genetics SA announced today the closing of a capital increase in excess of 1 Million EUR
Delphi Genetics SA announced today the closing of a capital increase in excess o
Collaboration between Delphi Genetics and Avaxia biologics (MA, USA)
Delphi Genetics will collaborate with Avaxia Biologics (Lexington, Massach
Delphi Genetics at Biofit (Lille, France)
Delphi Genetics will be present at Biofit (Lille, France) on 2 and 3
You are here : News
|< previous||next >|
15 Jun 2009
- Novel microbiological technique permits biosynthesis of proteins at higher yields and without reliance on antibiotics -
Charleroi, Belgium, June, 15, 2009 - Delphi Genetics SA (“Delphi”) today announced that the company has entered into an agreement with Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, for the manufacture of biological pharmaceuticals using Delphi’s patented StabyExpressTM technology.
StabyExpress is a new approach to stabilising the genetic machinery required to manufacture proteins, the raw materials at the heart of many modern biopharmaceuticals including vaccines, monoclonal antibodies and therapeutic proteins. Biopharmaceuticals represent a growing proportion of marketed drugs worldwide with 15 % of the worldwide pharmaceutical market.
Delphi’s StabyExpress technology improves the efficiency of protein manufacture and at a higher quality than alternative approaches.
Moreover, the technology avoids use of antibiotic resistance genes and is therefore in line with recent FDA and EMEA recommendations against the use of antibiotics in manufacturing of proteins for human and veterinary use. Many biological products currently in clinical development and licensed for sale rely on antibiotic resistance genes in the manufacturing process. The use of the StabyExpress avoids any concern regarding the use of antibiotic resistance and offers next generation biological products a more regulatory-consistent manufacturing strategy.
|< previous||next >|